-
公开(公告)号：US12043673B2
公开(公告)日：2024-07-23
申请号：US17503132
申请日：2021-10-15
Applicant: City of Hope
Inventor： John E. Shively , Lin Li , Maciej Kujawski , Piotr Swiderski
CPC classification number: C07K16/4283 , C07K16/283 , C07K16/2878 , C07K16/46 , C07K2317/24 , C07K2317/31 , C07K2317/52
Abstract: The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.
-
2.发明公开公开(公告)号：US20230190799A1
公开(公告)日：2023-06-22
申请号：US17870024
申请日：2022-07-21
Applicant: City of Hope
Inventor： John E. Shively , Maciej Kujawski , Seung E. Cha , Paul Yazaki
IPC: A61K35/17 , C07K16/30 , A61K31/664 , A61P35/00 , A61P1/00 , A61K38/20 , A61K38/17 , A61K39/395
CPC classification number: A61K35/17 , C07K16/3007 , A61K31/664 , A61P35/00 , A61P1/00 , A61K38/2013 , A61K38/1774 , A61K39/39558 , C07K2317/622 , C07K2317/55 , A61K2039/545
Abstract: Aspects of the present disclosure provide methods for treating a subject having a carcinoembryonic antigen (CEA)-positive tumor using a conditioning regimen (lymphodepleting treatment), which comprises administering one or more doses of a lymphodepleting agent to a subject, and a treatment regimen, which comprises administrating one or more doses of the anti-CEA CAR T cells and/or the ICK proteins to the subject.
-
公开(公告)号：US20220119552A1
公开(公告)日：2022-04-21
申请号：US17503132
申请日：2021-10-15
Applicant: City of Hope
Inventor： John E. Shively , Lin Li , Maciej Kujawski , Piotr Swiderski
Abstract: The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.
-
公开(公告)号：US10471161B2
公开(公告)日：2019-11-12
申请号：US14773733
申请日：2014-03-08
Inventor： Zibo Li , Peter S. Conti , Lin Li , Zhanhong Wu , Shuanlong Liu , John E. Shively , David Horne
Abstract: A thio-selective radioactive labeling agent has the following general formula: *R-L-VS, wherein said *R is a radioisotope, L is a linking group, and VS is a vinylsulfone functional group.
-
公开(公告)号：US20180155449A1
公开(公告)日：2018-06-07
申请号：US15707401
申请日：2017-09-18
Applicant: City of Hope
Inventor： Anna M. Wu , John E. Shively , Andrew A. Raubitschek , Mark A. Sherman , Tove Olafsen
IPC: C07K16/46 , C07K16/30 , C07K16/00 , A61K39/395 , A61K39/00
CPC classification number: C07K16/30 , A61K39/39558 , A61K2039/505 , C07K16/00 , C07K16/3007 , C07K16/46 , C07K2317/626 , C07K2317/64 , C07K2317/90 , C07K2319/00
Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable ⋅ carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
-
Patent Agency Ranking
6.发明申请GENERATION OF NOVEL BONE FORMING CELLS (MONOOSTEOPHILS) FROM LL-37 TREATED MONOCYTES 有权从LL-37处理的单核细胞中产生新的骨形成细胞（单体细胞）公开(公告)号：US20130315961A1
公开(公告)日：2013-11-28
申请号：US13955196
申请日：2013-07-31
Applicant: CITY OF HOPE
Inventor： Zhifang Zhang , John E. Shively
CPC classification number: A61K39/00 , A61K35/32 , A61K38/48 , C12N5/0654 , C12N2501/155 , C12N2501/998 , C12N2506/115
Abstract: In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils.
Abstract translation: 在一个实施方案中，提供了单核细胞衍生的骨形成细胞群体。 在一个实施方案中，细胞群体包含用有效剂量的LL-37处理的分离的单核细胞群体。 在另一个实施方案中，提供了一种产生单核细胞衍生的骨形成细胞群的方法。 该方法包括从受试者获得血样; 从血液样品中分离单核细胞群; 用有效剂量的LL-37处理分离的单核细胞; 并培养LL-37处理的单核细胞，直到它们分化成单核细胞衍生的骨形成细胞群体。 在另一个实施方案中，提供了治疗骨损伤或骨疾病的方法。 该方法包括向具有骨损伤或疾病的受试者施用治疗有效量的组合物，所述组合物包含单一嗜骨细胞群体。
-
公开(公告)号：US20230001027A1
公开(公告)日：2023-01-05
申请号：US17764708
申请日：2020-09-30
Applicant: City of Hope
Inventor： John E. Shively , Michael R. Weist , Bradley J. Ahrens , Lin Li , Weidong Hu
IPC: A61K51/04
Abstract: Provided herein, inter alia, are methods and compositions for detection of vascular calcification.
-
公开(公告)号：US10603328B2
公开(公告)日：2020-03-31
申请号：US15967442
申请日：2018-04-30
Applicant: City of Hope
Inventor： Zijie Sun , David Horne , Junfeng Li , John E. Shively , Jun Xie
Abstract: Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.
-
9.发明授权Generation of novel bone forming cells (monoosteophils) from LL-37 treated monocytes 有权从LL-37处理的单核细胞中产生新型骨形成细胞（单嗜性细胞）公开(公告)号：US09005969B2
公开(公告)日：2015-04-14
申请号：US13955196
申请日：2013-07-31
Applicant: City of Hope
Inventor： Zhifang Zhang , John E. Shively
CPC classification number: A61K39/00 , A61K35/32 , A61K38/48 , C12N5/0654 , C12N2501/155 , C12N2501/998 , C12N2506/115
Abstract: In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils.
Abstract translation: 在一个实施方案中，提供了单核细胞衍生的骨形成细胞群体。 在一个实施方案中，细胞群体包含用有效剂量的LL-37处理的分离的单核细胞群体。 在另一个实施方案中，提供了一种产生单核细胞衍生的骨形成细胞群的方法。 该方法包括从受试者获得血样; 从血液样品中分离单核细胞群; 用有效剂量的LL-37处理分离的单核细胞; 并培养LL-37处理的单核细胞，直到它们分化成单核细胞衍生的骨形成细胞群体。 在另一个实施方案中，提供了治疗骨损伤或骨疾病的方法。 该方法包括向具有骨损伤或疾病的受试者施用治疗有效量的组合物，所述组合物包含单一嗜骨细胞群体。
-
公开(公告)号：US20230256122A1
公开(公告)日：2023-08-17
申请号：US18145614
申请日：2022-12-22
Applicant: City of Hope
Inventor： John E. Shively , Maciej Kujawski , Megan Minnix , Paul Yazaki
CPC classification number: A61K51/1048 , A61K51/1096 , A61K47/6853 , A61K47/6813 , A61P35/00
Abstract: Provided herein, inter alia, are radionuclide-labeled antibodies, immunocytokines, and methods for treating cancer using combination therapy with the radionuclide-labeled antibodies and the immunocytokines.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.031 seconds)
